Fifteen years ago, Scholar Muthamia was getting ready to welcome her second child. The pregnancy had no complications at all and when her son Ferdinand Mutugi Njuguna was born, he weighed a healthy 3.9 kg.Mutugi was as precocious a toddler as can be, and all was fine in the Njuguna household until the boy developed a peculiar walking style.He would push his left foot ahead while walking and he didnt seem to quite stand up straight, Muthamia says.We thought it was a unique walking style he had developed, and let him be. And weirdly, when wearing a pair of shorts or trousers, he would pull them up with his arms while walking and many assumed we were buying him over-sized clothes, she says.Later, Ferdinand began falling while walking. He also started having a hard time standing up from a sitting position. Climbing stairs became a hardship and he couldnt run as fast as he used to.He would get tired very fast and even started walking on his toes. We took him to various hospitals and eventually ended up at Kenyatta National Hospital where he was diagnosed with Duchenne muscular dystrophy,she says.

For More of This and Other Stories, Grab Your Copy of the Standard Newspaper. Read Now

Do not miss out on the latest news. Join the Standard Digital Telegram channel HERE.

Read more:

The disease that wastes away boys muscles - Standard Digital

Andrew P. McMahonwho is the W.M. Keck Provost and University Professor in USCs departments of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine, and Biological Sciences at the Dornsife College of Letters, Arts and Scienceshas been elected as a new member of the National Academy of Sciences in honor of his outstanding contributions to developmental biology. The National Academy of Sciences brings together nearly 3,000 leading researchers to provide objective, science-based advice on critical issues affecting the nationin accordance with an Act of Congress approved by President Abraham Lincoln in 1863.

Were delighted that Dr. McMahon is being recognized as a newly elected member of the National Academy of Sciences, said Dean Laura Mosqueda from the Keck School. Because new members are elected by current members, this represents recognition of Dr. McMahons achievements by his most esteemed peers in all scientific fields.

Being elected to the National Academy of Sciences is one of the highest honors that can be bestowed upon a scientist. Dr. McMahon has had a truly remarkable career in the field of developmental biology. This honor is well deserved. We are proud of Dr. McMahons accomplishments and of his contributions to research and education at USC, said USC Provost Charles F. Zukoski.

McMahons group is well-known for identifying key signals coordinating cell interactions directing the assembly, composition and functional organization of mammalian organ systems. This research led to the founding of a biotechnology startup and the first drug treatment for an invasive form of skin cancer.

Currently, the McMahon Lab has narrowed its focus from multiple organ systems to a single, exquisitely complex organ: the kidney. With one in 10 people worldwide affected by chronic kidney disease, McMahon has a pragmatic desire to advance stem cell research in response to this medical need.

His lab has uncovered detailed genetic and molecular clues about how developing kidneys form, as well as how adult kidneys respond to injury and disease. These discoveries inform efforts to build synthetic mini kidneys, called organoids, that can be used to study disease, identify potential drug therapies, and eventually provide functional tissue for transplantation.

McMahon laid the groundwork for his career in developmental biology when he was still a high school student in the United Kingdom, studying for his university entrance exams.

The great thing about sitting the exam for Oxford University was that it excused me from taking the regular classes at school and allowed me to just read things that I thought were interesting, he said. So I started reading books about how our genes worked.

During his undergraduate studies at Oxford University, McMahon became fascinated by how genes orchestrated the intricate process of human embryonic development.

Im always looking for answers to what I consider to be the most interesting question of all, said McMahon. How do our genes direct one cell, the egg, to generate the remarkable diversity of different cell types in our bodies?

He continued this line of inquiry during his PhD studies at University College London, and his postdoctoral training at the California Institute of Technology. He started his independent research career at the National Institute for Medical Research in London, then moved to the Roche Institute for Molecular Biology, before joining the faculty at Harvard University in 1993.

After a nearly 20-year career at Harvard, McMahon joined USC as the Director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research in 2012. He established a new Department of Stem Cell Biology and Regenerative Medicine, which he chairs, and recruited a large cohort of early-career scientists at the start of their faculty careers.

In addition to his most recent accolade from the National Academy of Sciences, McMahon is an elected fellow of the American Association for the Advancement of Science, the American Academy of Arts and Sciences, the European Molecular Biology Organization, and the Royal Society.

His group has published more than 300 primary research articles, and 22 US patents and 30 foreign patents have been issued around his research.

It may be a clich, but its true: this recognition is really a recognition of the many talented students, postdoctoral fellows and research staff I have been privileged to work with at several institutions throughout my career, said McMahon. I am glad my good fortune continues at USC.

Read this article:

USC Professor Andrew P. McMahon elected to the National Academy of Sciences - USC News

For a few years now, scientists at Washington University have been working on techniques to turn stem cells into pancreatic beta cells as a way of addressing insulin shortages in diabetics. After some promising recent strides, the team is now reporting another exciting breakthrough, combining this technique with the CRISPR gene-editing tool to reverse the disease in mice.

The pancreas contains what are known as beta cells, which secrete insulin as a way of tempering spikes in blood-sugar levels. But in those with diabetes, these beta cells either die off or dont function as they should, which means sufferers have to rely on diet and or regular insulin injections to manage their blood-sugar levels instead.

One of the ways scientists are working to replenish these stocks of pancreatic beta cells is by making them out of human stem cells, which are versatile, blank slate-like cells that can mature into almost any type of cell in the human body. The Washington University team has operated at the vanguard of this technology with a number of key breakthroughs, most recently with a cell implantation technique that functionally cured mice with diabetes.

The researchers are continuing to press ahead in search of new and improved methods, and this led them to the CRISPR gene-editing system, which itself has shown real promise as a tool to treat diabetes. The hope was that CRISPR could be used to correct genetic defects leading to diabetes, combining with the stem cell therapy to produce even more effective results.

As a proof of concept, the scientists took skin cells from a patient with a rare genetic type of diabetes called Wolfram syndrome, which develops during childhood and typically involves multiple insulin injections each day. These skin cells were converted into induced pluripotent stem cells, which were in turn converted into insulin-secreting beta cells. But as an additional step, CRISPR was used to correct a genetic mutation that causes Wolfram syndrome.

These edited beta cells were then pitted against non-edited beta cells from the same batch in test tube experiments and in mice with a severe type of diabetes. The edited cells proved more efficient at secreting insulin and when implanted under the skin in mice, reportedly caused the diabetes to quickly disappear. The rodents that received the unedited beta cells remained diabetic.

This is the first time CRISPR has been used to fix a patients diabetes-causing genetic defect and successfully reverse diabetes, said co-senior investigator Jeffrey R. Millman. For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene. But we see this as a stepping stone toward applying gene therapy to a broader population of patients with diabetes.

The researchers are now continuing to work on improving the beta cell production technique, which in the future could involve cells taken form the blood or even urine, rather than the skin. They believe that further down the track this therapy could prove useful in treating both type 1 and type 2 diabetes, by correcting mutations that arise from genetic and environmental factors, and possibly be used to treat other conditions, as well.

We basically were able to use these cells to cure the problem, making normal beta cells by correcting this mutation, said co-senior investigator Fumihiko Urano. Its a proof of concept demonstrating that correcting gene defects that cause or contribute to diabetes in this case, in the Wolfram syndrome gene we can make beta cells that more effectively control blood sugar. Its also possible that by correcting the genetic defects in these cells, we may correct other problems Wolfram syndrome patients experience, such as visual impairment and neurodegeneration.

The research was published in the journal Science Translational Medicine.

Source: Washington University

Continued here:

CRISPR combines with stem cell therapy to reverse diabetes in mice - New Atlas

I dont know why people pay attention only to vaccines and treatments against the new coronavirus. Stem cell therapies are more useful to treat Covid-19.

So claimed Lee Hee-young, president of the Korean Association of Stemcell Therapy, at a news conference in Seoul, Monday. He called for active use of stem cell therapies to treat Covid-19 patients.

Several studies have proved the effects of autologous stem cells in treating acute respiratory distress syndrome (ARDS), which is the leading cause of death in Covid-19 patients, Lee said. The concept of stem cell therapy is the same as that of blood transfusion or bone marrow transplantation. Decades of cell therapies have proved that stem cell therapy is safe.

While the development of a treatment or a vaccine against Covid-19 takes a long time and it may not be able to treat patients immediately because of virus mutation possibilities, stem cell therapies can restore damaged lungs directly, Lee claimed.

It is more important to restore damaged lungs than to fight the virus. Stem cell therapy restores the lungs, giving patients time to beat the virus, he went on to say. However, people are paying attention to vaccine or treatment candidates only. This is why I am holding a news conference.

Lee pointed out that the local environment makes it difficult to use stem cell therapies. Thus, the government should ease regulations on the management and use of cell culture facilities so that doctors can perform stem cell therapies with simple cell culture, he said.

As long as physicians have a positive pressure facility and a culture kit, they can separate and culture cells with simple training, he said. If the authorities allow doctors to perform stem cell therapies with a disposable mobile culture autonomously, the cost of stem cell therapies will go down significantly.

Lee added that he asked related officials to include such rules in the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals, which is to take effect in the second half of the year.

same@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Read this article:

'Stem cell therapy more effective on Covid-19' - Korea Biomedical Review - Korea Biomedical Review

Ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) who were treated with intravenous infusions of an allogeneic mesenchymal stem cell product candidate had a survival rate of 83%.

The allogeneic mesenchymal stem cell product candidate remestemcel-L from Mesoblast Limited (Melbourne, Australia) was administered within the first five days under emergency compassionate use at New York Citys Mt Sinai hospital during the period March-April 2020. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at Mt Sinai hospital. 75% of the patents successfully came off ventilator support within a median of 10 days, in contrast to only 9% of ventilator-dependent COVID-19 patients being able to come off ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at two major referral hospital networks in New York during the same time period. These poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and moderate/severe ARDS.

The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS, said Mesoblast Chief Executive Dr. Silviu Itescu. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators, said Mesoblast Chief Medical Officer Dr Fred Grossman. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS.

Related Links:Mesoblast Limited

Follow this link:

Stem Cell Therapy Shows 83% Survival in COVID-19 Patients Dependent on Ventilator - HospiMedica

MIAMI (CBSMiami) A team of doctors at the University of Miami is working on what could be groundbreaking therapy for treating some COVID-19 patients.

With a focus on those suffering with severe lung inflammation, theyre using the umbilical system cells to treat patients.

For an update on how its progressing, Dr. Camillo Ricordi, a University of Miami professor and stem cell therapy researcher, joined Eliott Rodriguez and Rudabeh Shahbazi via Skype.

Q: This therapy is building off a 10-patient study in China and the results of that study are limited. So what information gave you hope that this would work on a broad scale?

A: Well, the information from this initial study have been incredibly encouraging. The editor in chief of the journal that did editorial on the paper presented commented as extraordinary results, but that need to be validated by law by lots of clinical trials. So were happy that FDA approved us to do such clinical trial at the University of Miami. And the nice thing is that well have the results in a very short time because these cells is like injecting anatomy of cells, 200 million cells, into those that will be fighting the complication of the infection and will know within weeks the there is a positive effect.

Q: How many patients are in the trial? When did you start? Have you seen any results so far?

A: We did. We have 24 patients in this initial trials. We didnt start the first patient, there have been only patients that are on compassionate release so far. And the initial results are coming from China and Israel. But we are ready to go. We have the terms the six doses already ready to be delivered and other 25 doses are ready to follow. So we have over as far as cell supply for the entire clinical trial, and we hope to have results very soon.

Q: So for the layman like us, can you explain how, why the stem cells infused in a vein end up in a lung?

A: Yeah, actually, this is a nice feature because when we do these trials, I directed Diabetes Research Institute at the University of Miami, so, traditionally, we did this trial for type 1 diabetes or for kidney disease. But in this case, when you inject the cells IV, intravenously, the first filter that is the lungs. So naturally the cells are trapped by the lungs as much as 95%. So in the case of targeting the pancreas or the kidney, you have to do an interventional radiology procedure to put a catheter in there that goes to these organs. But when you target the lung, this is a natural way of delivery and these cells form naturally to the lung. In addition, the cells sense inflammation and tissue injury, and hone, they go targeting specifically the site of tissue injury and inflammation. So in this case is even more relevant that in a simple intravenous, like a blood transfusion, will exactly target the lung, that is the organ that we want to treat

Q: How long do you expect to have to wait before you know if this was working?

A: Well, we know from the radiologic examination of the lungs from the studies in China, for example, that within days a resolution of the lung pathology.

Q: What is the typical recovery rate for COVID patients who have been put on a ventilator and is that meant to treat patients before they get to that critical stage?

A: Well, the typical recovery rate that we expect with this treatment is within a week we should know. So this is not a trial that we are required, like months or years of follow up to see if there is a beneficial effect or not. We are confident that within days or a week you will know if this is working or not as soon as we start.

Q: Is this is therapy meant to complement other forms of therapy?

A: I think it will definitely be used as a combination therapy. We dont exclude any other therapy as part of the combination therapy. With another agent that may help fight this is immune reaction, this pro-inflammatory reaction and also the problem that you see in micro-thromboembolism and the coagulation problem that you see in these patients. So I think is in a way is a unique therapy because its not just for COVID-19, but its for any virus targeting the lung with this massive reaction. So it will be something that we are planning in the future to create the repository for rapid intervention and integrated response to any pandemic or a situation in which you have an emergency that you need to treat an injury to the lung of such dimension. But in the meantime, when there is not a pandemic situation, you can use these cells. We have trials ongoing that has been authorized by the FDA for type 1 diabetes, Alzheimer, for kidney disease. So its a cell type that can be used in many other situations to start normal organ function, not just COVID-19.

Q: If this succeeds, how big of a deal is it?

A: If this succeeds, it will be a way to treat the severe cases of COVID-19 while we wait for a vaccine. But also to have a repository of cells that will be able to treat any other possible pandemic or epidemic where the lung will be a target of the viral attack. In this case, you have an army of cells that are ready to be used and fight this viral infection and all the consequences that can induce in the lungs.

RELATED:Current Curfews In South FloridaDrive-Through Testing LocationsTrack The Spread Of The Coronavirus In Real TimeHow To Make Your Own Face Mask

Originally posted here:

Coronavirus Q&A: Dr. Camillo Ricordi Gives Update On Trials Of Stem Cell Treatment For Most Severe COVID-19 Cases - CBS Miami

The Stem Cell Therapy Market Has Witnessed Continuous Growth In The Past Few Years And Is Projected To Grow Even Further During The Forecast Period (2020-2027). The Assessment Provides A 360 View And Insights, Outlining The Key Outcomes Of The Industry. These Insights Help The Business Decision-makers To Formulate Better Business Plans And Make Informed Decisions For Improved Profitability. In Addition, The Study Helps Venture Or Private Players In Understanding The Companies More Precisely To Make Better-informed Decisions. Some Of The Prominent Key Players Covered In The Stem Cell Therapy Market Are Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Whats Keeping Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc. Ahead In The Market? Benchmark Yourself With Strategic Steps And Conclusions Recently Published By Coherent Market Insights

Type Segmentation:

By Cell Source:Adult Stem CellsInduced Pluripotent Stem CellsEmbryonic Stem CellsOthersGlobal Stem Cell Therapy Market, By Application:Musculoskeletal DisordersWounds and InjuriesCancerAutoimmune disordersOthers

Consumer Traits (If Applicable)

The Stem Cell Therapy Market Study Covers Current Status, % Share, Future Patterns, Development Rate, Swot Examination, Sales Channels, To Anticipate Growth Scenarios For Years 2020-2027. It Aims To Recommend Analysis Of The Market With Regards To Growth Trends, Prospects, And Players Contribution To Market Development. The Report Size Market By 5 Major Regions, Known As, North America, Europe, Asia Pacific (Includes Asia & Oceania Separately), Middle East And Africa (Mea), And Latin America.

The Stem Cell Therapy Market Factors Described In This Report Are:-key Strategic Developments In Stem Cell Therapy Market: The Research Includes The Key Strategic Activities Such As R&d Plans, M&a Completed, Agreements, New Launches, Collaborations, Partnerships & (Jv) Joint Ventures, And Regional Growth Of The Key Competitors Operating In The Market At A Global And Regional Scale.

Key Market Features In Stem Cell Therapy Market: The Report Highlights Stem Cell Therapy Market Features, Including Revenue, Weighted Average Regional Price, Capacity Utilization Rate, Production Rate, Gross Margins, Consumption, Import & Export, Supply & Demand, Cost Bench-marking, Market Share, Cagr, And Gross Margin.

Analytical Market Highlights & Approach The Stem Cell Therapy Market Report Provides The Rigorously Studied And Evaluated Data Of The Top Industry Players And Their Scope In The Market By Means Of Several Analytical Tools. The Analytical Tools Such As Porters Five Forces Analysis, Feasibility Study, Swot Analysis, And Roi Analysis Have Been Practiced Reviewing The Growth Of The Key Players Operating In The Market.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2848

Table Of Contents:

Stem Cell Therapy Market Study Coverage: It Includes Major Manufacturers, Emerging Players Growth Story, Major Business Segments Of Stem Cell Therapy Market, Years Considered, And Research Objectives. Additionally, Segmentation On The Basis Of The Type Of Product, Application, And Technology.

Stem Cell Therapy Market Executive Summary: It Gives A Summary Of Overall Studies, Growth Rate, Available Market, Competitive Landscape, Market Drivers, Trends, And Issues, And Macroscopic Indicators.Stem Cell Therapy Market Production By Region Stem Cell Therapy Market Profile Of Manufacturers-players Are Studied On The Basis Of Swot, Their Products, Production, Value, Financials, And Other Vital Factors.

Key Points Covered In Stem Cell Therapy Market Report: Stem Cell Therapy Overview, Definition And Classification Market Drivers And Barriers

Stem Cell Therapy Market Competition By Manufacturers

Stem Cell Therapy Capacity, Production, Revenue (Value) By Region (2019-2027)

Stem Cell Therapy Supply (Production), Consumption, Export, Import By Region (2019-2027)

Stem Cell Therapy Production, Revenue (Value), Price Trend By Type {strip Sensors, Invasive Sensors, Ingestible Sensors, Implantable Sensors, Wearable Sensors}

Stem Cell Therapy Market Analysis By Application {hospitals, Ambulatory Surgical Centers, Diagnostic Centers}

Stem Cell Therapy Manufacturers Profiles/analysis Stem Cell Therapy Manufacturing Cost Analysis, Industrial/supply Chain Analysis, Sourcing Strategy And Downstream Buyers, Marketing Strategy By Key Manufacturers/players, Connected Distributors/traders Standardization, Regulatory And Collaborative Initiatives, Industry Road Map And Value Chain Market Effect Factors Analysis.

Get PDF Brochure Report + All Related Graphs & Charts @ https://www.coherentmarketinsights.com/insight/request-pdf/2848

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Originally posted here:

Impact of COVID-19 on Stem Cell Therapy Market Investment Opportunities And Forecast 2020-2027 | By Top Key Players Magellan, Medipost Co., Ltd,...

Given the debilitating impact of COVID-19 (Coronavirus) on the Animal Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Animal Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Animal Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Animal Stem Cell Therapy market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Animal Stem Cell Therapy market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Animal Stem Cell Therapy market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Regional Overview

Our team of analysts at PMR, trace the major developments within the Animal Stem Cell Therapy landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Animal Stem Cell Therapy market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Key Takeways Enclosed in the Report:

Queries Related to the Animal Stem Cell Therapy Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Why Opt for Persistence Market Research?

Read more here:

World coronavirus Dispatch: Animal Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2036 2017 2025 - Latest Herald

Mrinsights.bizhas published a new report titled GlobalAnimal Stem Cell TherapyMarketGrowth 2020-2025 which comprises new statistical data on the changing market scenario and initial and future assessment of the market. The report covers a wide range of business aspects global Animal Stem Cell Therapy trends, future forecasts, growth opportunities, key end-user industries, and market players. The report analyzes the recent developments, investment opportunities, and probable threats in the market. It closely looks at the markets all-purpose evaluation and depicts the important data associated with the global market.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/232664/request-sample

The report assesses the demand-side and supply-side trends in the global Animal Stem Cell Therapy market. Various segments are scrutinized that involve end-users, regions, and players on the basis of demand patterns, and prospect for 2020 to 2025 time-period. The research report contains a comprehensive database on future market estimation based on historical data analysis. Key players are listed with major collaborations, mergers & acquisitions and upcoming and trending innovation. Primary research involves interviews, news sources and information booths. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

Understanding The Competitive Scenario:

Competitive landscape analysis is presented which involves the global Animal Stem Cell Therapy market share of major players, along with the new projects and strategies adopted by players in the past five years. Comprehensive company profiles comprise the product offerings, key financial information, recent developments, SWOT analysis, capacity, production, price, revenue, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, and strategies employed by the major market players. Additionally, the report covers insights into the production and capacities in terms of manufacturing with price fluctuations of raw materials, process in-flow rate product cost, and production value.

Considering market analysis, the profiled list of companies in the report is:Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA, U.S. Stem Cell, Inc, VetCell Therapeutics, J-ARM, Kintaro Cells Power, Celavet Inc., Animal Stem Care, Magellan Stem Cells, Cell Therapy Sciences, Animacel

Currently, the research report gives special attention and focus on the following regions:Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries).

Moreover, the report identifies potential customers and suppliers as well as gives an analysis of the companys business structure, operations, major products and services, and business strategy. The study helps you understand the companys core strengths, weaknesses, opportunities, and threats. The report shows factual data about the global Animal Stem Cell Therapy market in the worldwide area, for example, production chain, manufacturing capacity, sales volume, and revenue.

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-animal-stem-cell-therapy-market-growth-2020-2025-232664.html

The Scope of The Global Animal Stem Cell Therapy Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Follow this link:

Global Animal Stem Cell Therapy Market 2020 Future Scenario, Industry Growth Insights and Production Analysis 2025 - Bandera County Courier

CAR-T and TCR-T therapies that involve engineering a patients own immune cells with antigen-specific receptors have revolutionized blood cancer treatment. Nowscientists at Duke-NUS Medical School are exploring the possibility of turning the approach against COVID-19.

The idea of using CAR/TCR-T cell therapy has already been proposed for treating chronic viral infections such as HIV and hepatitis B. Based on previous research, Antonio Bertoletti from Duke-NUS emerging infectious diseases research program suggest these immunotherapies might also be useful in treating SARS-CoV-2, the virus causing the current pandemic.

We demonstrated that T cells can be redirected to target the coronavirus responsible for SARS. Our team has now begun exploring the potential of CAR/TCR T cell immunotherapy for controlling the COVID-19-causing virus, SARS-CoV-2, and protecting patients from its symptomatic effects, Bertoletti said in a statement.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

These types of therapies involve modifying patients' own T cells with either a chimeric antigen receptor (CAR) or a T-cell receptor (TCR) that can recognize specific antigens associated with cancer,and then guiding the immune cells to eradicate the targets when infused back into the patients.

In a 2011 article published in the Journal of Virology, Bertoletti led a team that generated TCR-T cells that can go after SARS, another coronavirus that caused a deadly outbreak in China and other countries in late 2002 and early 2003.

The team showed that those TCR-redirected T cells displayed a functional profile similar to that of SARS-specific memory CD8 T cells from people who recovered from SARS-CoV infection. Based on the findings, the researchers suggested that TCR-T cells represent a promising prophylactic or therapeutic treatment for SARS.

RELATED:How 'duoCAR-T' cells could clear HIV and prevent resurgence of virus reservoirs

CAR-T cells have been explored in other viruses. A research team from the Albert Einstein College of Medicine and the University of Pittsburgh, for example,designed duoCAR-T cells that target three sites on the HIV envelope glycoprotein. In the lab, the cell therapy eliminated up to 99% of immune cells infected with different strains of HIV.

Despite thepromise of T-cell therapies, however, Bertoletti and colleague Anthony Tanoto Tan cautioned about potential safety concerns of using them to treat viral infections affecting vital organs. For one thing, CAR-T treatments havebeen linked to the dangerous side effect called cytokine release syndrome, in which overreactive immune cells launch an inflammatory response that can destroy organs, they said in a recent Journal of Experimental Medicine commentary. Similar cytokine storm effects have been reported in somesevere COVID-19 patients, leading to potentially life-threatening lung inflammations.

[T]he infusion ofT cells stably expressingpathogen-specific CAR/TCR poses therisk that these T cells might proliferate and wipe out all the infected cells that might be the majority of the infected organ, Bertoletti and Tanoto Tan wrote in their article.

To addressthat problem, Bertoletti and colleagues are using mRNA electroporation to engineer CAR/TCR T cells, which they say can limit their inflammatory capability and shorten the functional activity. That may offer a safer way to use engineered immune cells to treat viral diseases.

Several organizations are also working on cell therapies for COVID-19. AlloVir and Baylor College of Medicine have teamed up to develop an off-the-shelf therapy that entails exposing donor T cells to cytokines combined with viral fragments so the new cells can target the novel coronavirus. Celgene spinoff Celularity just started clinical trial of its cancer treatment CYNK-001 for COVID-19. The drugturns placental stem cells into one-size-fits-all natural killer cells.

Visit link:

Scientists explore using CAR-T and other engineered immune cells to target COVID-19 - FierceBiotech

DetailsCategory: DNA RNA and CellsPublished on Monday, 27 April 2020 17:10Hits: 34

BOSTON, MA, USAandLONDON, UK I April 27, 2020 IOrchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). The study is designed to evaluate safety, tolerability and clinical efficacy and is intended to enroll up to five patients between three months and 24 months of age who will be followed for three years. The study also contains a number of key secondary outcome measures such as overall survival, cognition and behavior to help inform future clinical development of HSC gene therapy in this indication.

MPS-IIIA, also known as Sanfilippo syndrome type A, is a rare, inherited neurometabolic disorder caused by genetic mutations that leads to the buildup of sugar molecules called mucopolysaccharides in the body, resulting in progressive intellectual disability and loss of motor function. Children born with MPS-IIIA rarely live past adolescence or early adulthood, and no approved therapies currently exist to treat the disease.

I am very encouraged that we, together with our research and clinical collaborators in Manchester, could achieve this important milestone in our efforts to develop a gene therapy for MPS-IIIA despite the current, challenging global health circumstances, saidBobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. It is a testament to the dedication of our collective teams and underscores the truly dire, life-limiting nature of the disease for affected children and their families. This study adds to Orchards clinical pipeline of HSC gene therapies for the treatment of severe neurometabolic disorders and further demonstrates the potential of our platform approach.

About MPS-IIIAMucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A) is a rare and life-threatening metabolic disease. People with MPS-IIIA are born with a mutation in theN-sulphoglucosamine sulphohydrolase (SGSH)gene, which, when healthy, helps the body break down sugar molecules called mucopolysaccharides. The buildup of mucopolysaccharides in the brain and other tissues leads to intellectual disability and loss of motor function. MPS-IIIA occurs in approximately one in every 100,000 live births. Life expectancy of children born with MPS-IIIA is estimated to be between 10-25 years.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

SOURCE: Orchard Therapeutics

Continued here:

Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA) |...

Pluristem Therapeutics or PLX cell therapyuses placentas to grow smart cells, and programs them to secrete therapeutic proteins in the bodies of sick people. It has just treated its first American COVID-19 patient after treating seven Israelis. The patients were suffering from acute respiratory failure and inflammatory complications associated with Covid-19. Now, this theraphy is being touted as a possible 'cure'' for the deadly coronavirus with scientisst conducting varied researches on the same. In an exclusive interaction with India TV, doctors from India and abroadcame together for discussing about how effective can cell therapy be in treating coronavirus. Dr Solomon from Israel, Dr Anil Kaul from the US, DrSanjeev Chaubey from Shanghai and Dr Padma Srivastv and Dr Harsh Mahajan from India threw light upon the stem cell therapy and the possibility of incorporating the same in treating COVID-19 pateints.

Latest News on Coronavirus

Fight against Coronavirus: Full coverage

Read more:

How effective is PLX cell therapy in treating coronavirus? Experts answer all queries and more - India TV News

New research finds a connection between destructive white blood cells and a more severe disease course in patients with COVID-19.

"We found that patients with COVID-19 infection have higher blood levels of neutrophil extracellular traps, also called NETs, which are a product of an inflammatory type of neutrophil cell death called NETosis," says first author Yu (Ray) Zuo, M.D., a Michigan Medicine rheumatologist.

Zuo worked on the study with Yogen Kanthi, M.D., a cardiologist and vascular medicine specialist at the Michigan Medicine Frankel Cardiovascular Center, and Jason Knight, M.D., Ph.D., a rheumatologist at Michigan Medicine, who study inflammation and neutrophils. The researchers analyzed blood samples from 50 patients with COVID-19 for this publication.

Zuo and colleagues say, in light of the COVID-19 pandemic, there is an urgent need to better understand what causes the inflammatory storm and blood clots triggered by SARS-CoV-2 infection--a storm that leads to respiratory failure and a requirement for mechanical ventilation in many patients. They believe NETs may be relevant to many aspects of COVID-19 research, given that thrombosis and inflammation are hallmarks of severe infection.

This is the first publication to come out of the Frankel CVC's CV Impact Research Ignitor Grant program, which was created to address COVID-19 from both basic science and clinical perspectives.

Reference:Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., . . . Knight, J. S. (2020). Neutrophil extracellular traps in COVID-19. JCI Insight. doi:10.1172/jci.insight.138999

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to read the rest:

Higher Levels of NETs in Blood Associated With More Severe COVID-19 - Technology Networks

Allosource

Global Stem Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=002

Stem Cell Therapy Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Stem Cell Therapy industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Stem Cell Therapy industry.

-> Furthermore, we will help you to identify any crucial trends to predict Stem Cell Therapy market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Stem Cell Therapy market.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=002

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Stem Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Stem Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Stem Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

See the rest here:

Stem Cell Therapy Market Segmentation, Application, Technology, Analysis Research Report and Forecast to 2026 - Cole of Duty

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Go here to see the original:

Stem Cell Therapy Market to Discern Steadfast Expansion During 2025 - Cole of Duty

DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The Nerve Repair and Regeneration market worldwide is projected to grow by US$7.1 Billion, driven by a compounded growth of 12.1%. Neurostimulation & Neuromodulation Devices, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the region's size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/dhc95v

Read the original:

Global Nerve Repair and Regeneration Market (2019 to 2025) - Analysis, Trends, and Forecasts - ResearchAndMarkets.com - Business Wire

Adipose Derived Stem Cell Therapy Market Research Report 2020, is mostly driven by the improved taking on of Adipose Derived Stem Cell Therapy across small and medium-sized enterprises. Worldwide Adipose Derived Stem Cell Therapy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Adipose Derived Stem Cell Therapy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2357

About Adipose Derived Stem Cell Therapy Market Report

This research report categorizes the global Adipose Derived Stem Cell Therapy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

Adipose Derived Stem Cell Therapy Market Dynamics in the world mainly, the worldwide 2020-2026 Adipose Derived Stem Cell Therapy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Adipose Derived Stem Cell Therapy Market Report:

Adipose Derived Stem Cell Therapy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Adipose Derived Stem Cell Therapy, Market Driving Factor Analysis of Adipose Derived Stem Cell Therapy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Adipose Derived Stem Cell Therapy, and Cost and Gross Margin Analysis of Adipose Derived Stem Cell Therapy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Adipose Derived Stem Cell Therapy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Adipose Derived Stem Cell Therapy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Adipose Derived Stem Cell Therapy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2357

Further in the report, the Adipose Derived Stem Cell Therapy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Adipose Derived Stem Cell Therapy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Adipose Derived Stem Cell Therapy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Originally posted here:

Adipose Derived Stem Cell Therapy Market Increasing the Growth Worldwide: Industry Analysis, Growth, Drivers, Limitations, Regions, Forecast 2026 ...

Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the Harvard University team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospital's Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely.

For the new study, Harvard researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper.

These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita. These compounds boosted TERC levels in those stem cells and restored telomeres to their normal length. However, rather than a scattergun approach, the team really wanted to test for safety and see if the treatment could precisely target stem cells carrying the right ingredients for telomerase formation.

More specifically, the team wanted to see if this could be achieved by having the PAPD5-inhibiting drugs recognize and respond to another important component of telomerase, a molecule called TERT. To do so, in the next round of experiments the team used human blood stem cells and triggered mutations in the PARN gene that give rise to dyskeratosis congenita. These were then implanted into mice that were treated with the compounds, with the team finding the treatment boosted TERC, restored telomere length in the stem cells and had no ill effects on the rodents.

This provided the hope that this could become a clinical treatment, says Nagpal.

The team will now continue its work in an effort to prove these small molecules are a safe and effective way to apply the brakes to dyskeratosis congenita, other diseases, and possibly aging more broadly.

We envision these to be a new class of oral medicines that target stem cells throughout the body, Agarwal says. We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.

The research was published in the journal Cell Stem Cell.

Source: Boston Childrens Hospital via Harvard University

See the original post here:

Molecules identified that reverse cellular aging process - New Atlas

The presented market report on the global Rheumatoid Arthritis Stem Cell Therapy market published by Fact.MR is a comprehensive analysis of the leading parameters that are likely to determine the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the forthcoming decade. Further, the study dives in deep to investigate the micro and macro-economic factors that are projected to influence the global scenario of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period (2019-2029).

The market study reveals that the Rheumatoid Arthritis Stem Cell Therapy market is expected to grow at a CAGR of ~XX% and reach a value of ~USXX by the end of 2029. The report examines the current trends, growth opportunities, restraints, and market drivers that are projected to influence the overall dynamics of the Rheumatoid Arthritis Stem Cell Therapy market in the assessment period. The market study predicts the course of the global Rheumatoid Arthritis Stem Cell Therapy market post the COVID-19 pandemic and offers resourceful insights to market players pertaining to their business continuity strategies and more.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market Segmentation

The report bifurcates the Rheumatoid Arthritis Stem Cell Therapy market into multiple segments to provide a clear picture of the Rheumatoid Arthritis Stem Cell Therapy market at a granular level. The key segments covered in the report include region, product type, application, and more.

Competitive landscape

The growth projection of each of these segments and sub-segments is accurately tracked in the report along with east-to-understand graphs and tables. Further, the market share, size, value, and Y-o-Y growth of the Rheumatoid Arthritis Stem Cell Therapy market segments are included in the report.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Essential Takeaways from the Rheumatoid Arthritis Stem Cell Therapy Market Report

Important queries related to the Rheumatoid Arthritis Stem Cell Therapy market addressed in the report:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Why Choose Fact.MR

Excerpt from:

Potential Impact of COVID-19 on Rheumatoid Arthritis Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2034 2018 to 2028 -...

Mount Sinai Health System announced that they will be using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy, in patients with coronavirus disease 2019 (COVID-19).

Additionally, Mount Sinai indicated that they will play a central role in a clinical trial for patients with severe acute respiratory distress syndrome, which affects individuals with severe cases of COVID-19.

Remestemcel-L has previously been tested in patients who have had a bone marrow transplant, who can experience an overactive immune response similar to that observed in severe cases of COVID-19.

Mount Sinai began administering remestemcel-L to patients in late March under the FDAs compassionate use program. The therapy was given to 10 patients with moderate to severe cases of COVID-19-related acute respiratory distress syndrome (ARDS), most of whom were on ventilators, and the doctors saw encouraging results.

We are encouraged by what we have seen so far and look forward to participating in the randomized controlled trial starting soon that would better indicate whether this is an effective therapy for patients in severe respiratory distress from COVID-19, Keren Osman, MD, medical director of the Cellular Therapy Service in the Bone Marrow and Stem Cell Transplantation Program at The Tisch Cancer Institute at Mount Sinai and associate professor of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, said in a press release.

The randomized clinical trial evaluating the therapeutic benefit and safety of remestemcel-L will be conducted at Mount Sinai, which will serve as the clinical and data coordinating center. The stem cell therapy will be evaluated in 240 patients with COVID-19-related ARDS in the US and Canada. Moreover, the trial will be conducted as a public-private partnership between the Cardiothoracic Surgical Trials Network.

The coronavirus pandemic has caused exponential increases of people suffering with acute respiratory distress syndrome, requiring intubation and mechanical ventilation with many dying, Annetine Gelijns, PhD, the Edmond A. Guggenheim Professor of Health Policy at the Icahn School of Medicine at Mount Sinai, said in a press release. We have designed a clinical trial that will expeditiously determine whether the stem cell therapy will offer a life-saving therapy for a group of patients with a dismal prognosis.

Remestemcel-L consists of mesenchymal stem cells. The therapy was previously assessed in a phase III trial in children who had graft-versus-host disease (GVHD), which can occur after bone marrow transplants. Further, the inflammation that occurs in GVHD is the result of a cytokine storm. A similar cytokine storm has been found to take place in patients with COVID-19 who develop acute respiratory distress syndrome.

These stem cells have shown excellent response rates in severe graft-versus-host disease in children, John Levine, MD, professor of Hematology, Medical Oncology, and Pediatrics at the Icahn School of Medicine at Mount Sinai, who is also the co-director of the Mount Sinai Acute GVHD International Consortium (MAGIC), said in a press release. Mesenchymal stem cells have a natural property that dampens excessive immune responses.

Some institutions have also begun testing anti-IL-6 agents, such as tocilizumab (Actemra), for the treatment of cytokine release syndrome in patients with COVID-19 who develop acute respiratory distress syndrome.

Reference:

Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients [news release]. New York, NY. Published April 9, 2020. newswise.com/coronavirus/mount-sinai-leading-the-way-in-innovative-stem-cell-therapy-for-covid-19-patients/?article_id=729684&sc=dwhr&xy=10019792. Accessed April 15, 2020.

Read the original post:

Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19 - Cancer Network